Singapore, Oct. 20 -- The Health Sciences Authority received information related to the study titled 'A PHASE III, MULTICENTER, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY ... Read More
Singapore, Oct. 20 -- The Health Sciences Authority received information related to the study titled 'An Interventional Phase 3, Open Label, Randomized Study To Evaluate Efficacy And Safety of PF-0863... Read More
Singapore, Oct. 20 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy Wi... Read More
Singapore, Oct. 20 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Ver... Read More
Singapore, Oct. 20 -- The Health Sciences Authority received information related to the study titled 'Characteristics and durability of immune response to fractional dose compared to standard dose Yel... Read More
Singapore, Oct. 20 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, two-part, double-blind, randomized, placebo-controlled study to investigate the safety ... Read More
Singapore, Oct. 20 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, double-blind, randomized, placebo controlled, 2-arm study to investigate the safety and... Read More
Singapore, Oct. 20 -- The Health Sciences Authority received information related to the study titled 'The use of Landiolol in mitral valve sUrgery: a raNdomized, controlled, double-blind triAl. (LUNA)... Read More
Singapore, Oct. 20 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment with AZD0... Read More
Singapore, Oct. 20 -- The Health Sciences Authority received information related to the study titled 'A Phase 1/1b Study of IAM1363 in Participants with Advanced Cancers Harboring HER2 Alterations'. T... Read More